Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ondine Biomedical, Inc. ( (GB:OBI) ) just unveiled an announcement.
Ondine Biomedical Inc. reported significant commercial expansion and clinical progress in the first half of 2025, with a 41% increase in the adoption of its Steriwave® technology across hospitals, including major Canadian and NHS sites. The company is advancing its largest clinical program, a U.S. Phase 3 trial, to support FDA submission, and has completed its first ICU-based Steriwave trial, indicating potential for broader clinical application in critical care. Financially, Ondine saw an 18% increase in revenue to $1.01 million, though operational losses rose due to trial costs. The company secured additional capital, strengthening its financial position, and is focused on expanding its market presence and operational capabilities to support long-term growth.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products based on its proprietary photodisinfection technology in various stages of development. Its nasal photodisinfection system, Steriwave®, is CE-marked in Europe and approved in several countries, including Canada, the UK, and Australia, for nasal decolonization.
Average Trading Volume: 370,875
Technical Sentiment Signal: Buy
Current Market Cap: £75.16M
See more data about OBI stock on TipRanks’ Stock Analysis page.